COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 15, 2022
Data from the CDC on US vaccination and booster shot rates and from the Johns Hopkins COVID-19 interactive map on cases and deaths in the US and worldwide.
Tirzepatide Reduces Time to HbA1c Targets by Up to 3 Months vs Semaglutide, Insulin Degludec
Tirzepatide in an exploratory analysis of SURPASS-2 and -3 trials added proof of shorter time to glycemic targets and weight loss goals to superior reduction of HbA1c.
The Brunt of the Long COVID Patient Burden May Fall on Primary Care, says Rehabilitation Medicine Expert
NYU Langone Rusk Rehabilitation medical director Steven Flanagan, MD, discusses the "second crisis" of the pandemic and the impact on primary care.
COPD: Pulmonary Rehab is Effective Regardless of Inhaled Triple Therapy Use
In-hospital pulmonary rehabilitation improves function and symptoms in COPD patients whether they are on triple therapy or not, a new study confirms.
Arthritis in Older Adults: Patient Thoughts on Symptoms, Management, & Clinician Counseling
New findings from a national survey shed light on patient attitudes and experiences with arthritis and joint pain.
Finerenone: FDA Expands Label to Include Cardiovascular Outcomes Trial Data
Data from the pivotal phase 3 FIGARO-DKD cardiovascular outcomes trial with finerenone reaffirms the agent's dual cardiorenal risk reduction benefits in T2D-associated CKD.
Long COVID Presents Many More Questions than Answers, says AAPM&R President-elect Flanagan
Long COVID symptoms are reported by persons who have had only mild disease, who have been vaccinated and boosted, and even those who had asymptomatic infection.
Cumulative Load of Systolic BP May Better Predict CV Risk in T2D Patients vs Standard BP Measures
In patients with type 2 diabetes, for every standard deviation increase in cumulative SBP load there was an increase of at least 10% in CV risk, a new study found.
Urban Areas in US are Associated with Lower Rates of Hypertension Medication Adherence, New Study Finds
AHA Hypertension 2022: New research showed that hypertension medication adherence was nearly 76% in large urban areas and increased as population density decreased.
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 13, 2022
The "Ugly Face" of Long COVID: A Conversation with Steven Flanagan, MD, President-elect, AAPM&R
The American Academy of Physical Medicine and Rehabilitation is a leading voice in the campaign for a national plan to address long COVID.
Early-onset Type 2 Diabetes Linked to Significantly Increased Risk for CVD in Later Life: Study
A 5-fold greater risk for all-cause or CVD-related death in persons diagnosed with T2D before age 40 years should be a call to action for enhanced screening, study authors state.
Two-thirds of Older Adults with Arthritis Use OTC Treatments, yet Many Do not Consult with Clinician about Medication Risks
Findings from the University of Michigan National Poll on Healthy Aging highlight the need for clinicians to raise the topic of joint pain with their older patients.
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 12, 2022
Decline in Physical Function Independently Associated with CVD Risk in Older Adults: ARIC Analysis
Physical performance scores used as a proxy for function in adults aged >65 years improved CVD risk prediction beyond traditional risk factors, study authors report.
Artificial Sweetener Intake Linked to Increased Risk of CVD in Large, Population-based Analysis
Artificial sweeteners should not be considered a healthy and safe alternative to sugar, caution French investigators.
Abelacimab Receives Fast Track Designation from FDA for Prevention of Stroke, Systemic Embolism in Patients with Atrial Fibrillation
Abelacimab is a dual-acting, fully human monoclonal antibody that selectively targets both factor XI and factor XIa with high affinity.
COVID-19 Update: US Vaccinations, Booster Doses, & Global Data as of September 9, 2022
Hypertension Treatment is Cost-effective for CVD Prevention, Whether the Target is from ACC/AHA or JNC 7, Study Reveals
Reducing blood pressure to 140/90 mm Hg or 130/80 mm Hg in high-risk patients proved either cost-saving or cost-effective at 10 years in a simulation study.
COVID-19 Bivalent Booster Shot Q&A for Clinicians
Get answers to 7 questions you may have regarding bivalent booster dose vaccination for patients from the US Centers for Disease Control and Prevention.